Advaxis to raise US$20mln as it looks to advance portfolio of cancer treatments

Last week Advaxis submitted a European marketing application or its lead product Axalimogene Filolisbac in cervical cancer patients, but it wants to develop it further for use in other indications

cancer cell under microscope
The company’s Lm-based immunotherapies work by encouraging bacteria in the body to generate cancer-killing T cells

Junior biotech Advaxis Inc (NASDAQ:ADXS) is looking to raise US$20mln from investors as it looks to develop and expand its pipeline of anti-cancer drugs.

The Princeton, New Jersey-based group is to sell 10mln shares at a price of US$2, a 20% discount to Wednesday’s closing price of of US$2.51.

Advaxis has also granted the underwriters a 30-day option to buy up to a further 807,697 shares at the same price which would bring in another US$1.6mln or so.

The money will be used to fund its various research and development programmes, including its lead product, Axalimogene Filolisbac, for which it submitted a European marketing application last week.

That application was for use as a second-line treatment in women with recurrent or metastatic cervical cancer but Advaxis is also looking to develop the drug for use in other cancer indications and possibly as one part of a combination therapy.

Advaxis shares fell 26.1% to US$1.85 - taking them below the offer price.

Quick facts: Advaxis

Price: 0.4336 USD

Market: NASDAQ
Market Cap: $28.72 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Davide Bosio previews hotly anticipated IPOs for Miramar Resources and Zebit

Davide Bosio from Shaw and Partners says it's been a terrific start to the listing process for Miramar Resources, a junior West Australia exploration company. ''We opened up the offer and closed literally on the same day raising $8mln''. Bosio adds that Zebit is still on track to list on the ASX...

20 hours, 48 minutes ago

2 min read